Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × tremelimumab × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 70 Thoracic 42 Genitourinary 31 Head & Neck 22 Dermatologic 17 Other solid neoplasm 11 Breast 11 Gynecologic 10 Tumor-Agnostic 3 Sarcoma 3 Endocrine 3 Lymphoid 2 Plasma cell 1 Other hematologic neoplasm 1 NET 1 CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 37 Everolimus 33 Magnetic Resonance Spectroscopy 17 Temozolomide 14 gallium Ga 68 dotatate 13 lanreotide 12 Octreotide 12 Nivolumab 11 Capecitabine 11 177Lu-octreotide, DOTA(0)-Tyr(3)- 11 pembrolizumab 9 Specimen Handling 9 surufatinib 8 cabozantinib 8 Sunitinib 8 pasireotide 7 Positron Emission Tomography Computed Tomography 7 3-Iodobenzylguanidine 7 Lutetium-177 6 Fluorodeoxyglucose F18 6 90Y-octreotide, DOTA-Tyr(3)- 6 amino-acid, glucose, and electrolyte solution 5 Ipilimumab 5 Injections 5 Ga(III)-DOTATOC 5 Etoposide 5 Carboplatin 5 olaparib 4 copper dotatate CU-64 4 avelumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡